Literature DB >> 27752929

miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.

Naeim Ehtesham1, Fariborz Khorvash2, Majid Kheirollahi3.   

Abstract

MicroRNAs (miRNAs) are crucial to the immunopathogenesis of multiple sclerosis (MS). The mechanism of action of interferon beta (IFN-β) in relapsing-remitting (RR) MS patients is largely unknown. miR-145 and miR-20a-5p previously reported as diagnosis biomarker in treatment naïve RRMS patients and their expression after IFN-β therapy might be indicative of molecular mechanism of IFN-β. Cross-talking between JAK/STAT pathway and complementary pathways like MAPK is important in IFN-β signaling. Here, in order to clarify the ambiguous molecular mechanism of IFN-β and evaluate the potential use of them as a biomarker for monitoring of therapy, we investigated the expression of miR-145 and miR-20a-5p in blood sample of 15 treatment naïve RRMS patients, 15 IFN-β-treated RRMS patients, and 15 healthy volunteers (HVs). In silico molecular signaling pathway enrichment analysis was fulfilled on validated and predicted targets of miR-145 and miR-20a-5p to probe the plausible role of them on molecular effects of IFN-β. We identified miR-145 and miR-20a-5p level was normalized in IFN-β-treated patients, and MAPK pathway was one of the most relevant pathways that recognized by molecular signaling pathway enrichment analysis. Moreover, ROC curve analysis of miR-145 indicated that this miRNA could be used for monitoring of response to IFN-β therapy. Restoration of miR-145 and miR-20a expression in IFN-β-treated patients suggests that pleiotropic effects of IFN-β might be through miRNAs. Enrichment of MAPK pathway underscores the importance of non-canonical pathways in IFN-β signaling.

Entities:  

Keywords:  Interferon-beta; MAPK pathway; MicroRNA; Multiple sclerosis

Mesh:

Substances:

Year:  2016        PMID: 27752929     DOI: 10.1007/s12031-016-0851-3

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  47 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 3.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

4.  Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.

Authors:  Uta Drebber; Max Lay; Inga Wedemeyer; Daniel Vallböhmer; Elfriede Bollschweiler; Jan Brabender; Stefan P Mönig; Arnulf H Hölscher; Hans P Dienes; Margarete Odenthal
Journal:  Int J Oncol       Date:  2011-05-10       Impact factor: 5.650

5.  MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy.

Authors:  Michael Augustine Ko; Guan Zehong; Carl Virtanen; Maha Guindi; Thomas K Waddell; Shaf Keshavjee; Gail E Darling
Journal:  Ann Thorac Surg       Date:  2012-08-29       Impact factor: 4.330

Review 6.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

7.  MiR-126: a novel route for natalizumab action?

Authors:  Maria Meira; Claudia Sievers; Francine Hoffmann; Tobias Derfuss; Jens Kuhle; Ludwig Kappos; Raija L P Lindberg
Journal:  Mult Scler       Date:  2014-03-05       Impact factor: 6.312

8.  Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Authors:  Anne Waschbisch; Monika Atiya; Ralf A Linker; Sergej Potapov; Stefan Schwab; Tobias Derfuss
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

9.  MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.

Authors:  Roberta Mancuso; Ambra Hernis; Simone Agostini; Marco Rovaris; Domenico Caputo; Mario Clerici
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

10.  Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.

Authors:  Jens Ingwersen; Til Menge; Britta Wingerath; Derya Kaya; Jonas Graf; Tim Prozorovski; Andreas Keller; Christina Backes; Markus Beier; Matthias Scheffler; Thomas Dehmel; Bernd C Kieseier; Hans-Peter Hartung; Patrick Küry; Orhan Aktas
Journal:  Ann Clin Transl Neurol       Date:  2014-12-05       Impact factor: 4.511

View more
  7 in total

1.  microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate.

Authors:  María I Dominguez-Mozo; Ignacio Casanova; Laura De Torres; Yolanda Aladro-Benito; Silvia Perez-Perez; Angel Garcia-Martínez; Patricia Gomez; Sara Abellan; Esther De Antonio; Carlos Lopez-De-Silanes; Roberto Alvarez-Lafuente
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

Review 2.  The role of microRNAs in diseases and related signaling pathways.

Authors:  Atena Vaghf; Behzad Khansarinejad; Ehsanollah Ghaznavi-Rad; Mahdieh Mondanizadeh
Journal:  Mol Biol Rep       Date:  2021-10-31       Impact factor: 2.742

3.  Elevated microRNA-145 inhibits the development of oral squamous cell carcinoma through inactivating ERK/MAPK signaling pathway by down-regulating HOXA1.

Authors:  Junhai Ding; Dubin Sun; Pengfeng Xie
Journal:  Biosci Rep       Date:  2019-06-25       Impact factor: 3.976

Review 4.  Environmental Influencers, MicroRNA, and Multiple Sclerosis.

Authors:  Eiman Ma Mohammed
Journal:  J Cent Nerv Syst Dis       Date:  2020-01-20

5.  miR-20a suppresses Treg differentiation by targeting Map3k9 in experimental autoimmune encephalomyelitis.

Authors:  Yishu Wang; Chong Xie; Yaying Song; Weiwei Xiang; Jing Peng; Lu Han; Jie Ding; Yangtai Guan
Journal:  J Transl Med       Date:  2021-05-26       Impact factor: 5.531

Review 6.  Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs' World.

Authors:  Nicoletta Nuzziello; Loredana Ciaccia; Maria Liguori
Journal:  Cells       Date:  2019-12-27       Impact factor: 6.600

7.  Expression and clinical significance of IL7R, NFATc2, and RNF213 in familial and sporadic multiple sclerosis.

Authors:  Seyedeh Zahra Hosseini Imani; Zohreh Hojati; Sheyda Khalilian; Fariba Dehghanian; Majid Kheirollahi; Mehdi Khorrami; Vahid Shaygannejad; Omid Mirmosayyeb
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.